Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer

Trends of risk classification and primary therapy for Japanese patients with prostate cancer in Nara Uro-Oncological Research Group (NUORG)–a comparison between 2004-2006 and 2007-2009

(2013) Nobumichi Tanaka et al.   BMC CANCER

Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy

(2011) Shu-Pin Huang et al.   PROSTATE

Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis

(2011) T Sasaki et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Trends of the Primary Therapy for Patients with Prostate Cancer in Nara Uro-oncological Research Group (NUORG): A Comparison Between the CaPSURE Data and the NUORG Data

(2010) N. Tanaka et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy

(2009) Toni K. Choueiri et al.   CANCER

Failing to achieve a nadir prostate-specific antigen after combined androgen blockade: Predictive factors

(2009) Seung Chol Park et al.   INTERNATIONAL JOURNAL OF UROLOGY

Prostate-Specific Antigen Progression Predicts Overall Survival in Patients With Metastatic Prostate Cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916

(2009) Maha Hussain et al.   JOURNAL OF CLINICAL ONCOLOGY

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY